These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16965911)

  • 21. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.
    Hatiboglu G; Hohenfellner M; Arslan A; Hadaschik B; Teber D; Radtke JP; Hallscheidt P; Tolstov Y; Roth W; Grüllich C; Huesing J; Duensing S; Pahernik S
    Langenbecks Arch Surg; 2017 Jun; 402(4):637-644. PubMed ID: 28012035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 23. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
    Gore ME; Escudier B
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):19-24. PubMed ID: 16773841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
    Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
    Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
    Maksimovic O; Schraml C; Hartmann JT; Bitzer M; Claussen CD; Pintoffl J; Horger M
    AJR Am J Roentgenol; 2010 Jan; 194(1):5-14. PubMed ID: 20028898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
    Desar IM; Jacobs JH; Hulsbergen-vandeKaa CA; Oyen WJ; Mulders PF; van der Graaf WT; Adema GJ; van Herpen CM; de Vries IJ
    Int J Cancer; 2011 Jul; 129(2):507-12. PubMed ID: 20839259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Shaheen PE; Rini BI; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
    Zhang HL; Zhu Y; Wang CF; Yao XD; Zhang SL; Dai B; Shen YJ; Zhu YP; Shi GH; Ye DW
    Int J Urol; 2011 Jun; 18(6):422-30. PubMed ID: 21481012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
    Kasibhatla M; Steinberg P; Meyer J; Ernstoff MS; George DJ
    Clin Genitourin Cancer; 2007 Mar; 5(4):291-4. PubMed ID: 17553211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
    Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
    BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2014 Sep; 49(9):601-7. PubMed ID: 24691140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
    Amato R; Zhai J; Willis J; Saxena S; DeFoe M
    Clin Genitourin Cancer; 2012 Sep; 10(3):153-8. PubMed ID: 22551785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
    Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
    BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
    Imarisio I; Paglino C; Ganini C; Magnani L; Caccialanza R; Porta C
    Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
    Lind JS; Meijerink MR; Dingemans AM; van Kuijk C; Ollers MC; de Ruysscher D; Postmus PE; Smit EF
    Eur Radiol; 2010 Dec; 20(12):2890-8. PubMed ID: 20625738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer.
    Hudson JM; Williams R; Karshafian R; Milot L; Atri M; Burns PN; Bjarnason GA
    Invest Radiol; 2014 Feb; 49(2):116-23. PubMed ID: 24220251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment.
    Lassau N; Chami L; Benatsou B; Peronneau P; Roche A
    Eur Radiol; 2007 Dec; 17 Suppl 6():F89-98. PubMed ID: 18376462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.